Network Italiano per la Bioterapia dei Tumori
In the team of the Laboratory of Immune Biological Therapy, at Sidra Medicine we are seeking a well trained and highly motivated scientist.
The candidate should have a PhD in Immunology or related field, and at least 5 years of post-doctoral experience in the biomedical research.
Qualified candidates should have prior experience in cancer immunology and immunotherapy, ex vivo characterization of T cell-mediated responses, flow cytometry,
in vitro functional assays, molecular biology and manipulations of plasmids and lentiviral vectors, as well as ability to analyze data and perform statistical analyses.
The knowledge of basic bioinformatics analysis will be a preferred skill.
The candidate will work under the supervision of Dr. Cristina Maccalli, Principal Investigator, within a multidisciplinary team of translational scientists,
computational biologists, and clinicians at the Research Department of Sidra Medicine, Doha, Qatar.
The research projects performed in Cristina Maccalli’s lab are focused on: 1. the development of immune cell-based therapy for cancer patients;
2. the identification of the cancer mechanisms of resistance to immunotherapy and the functional and immunological characterization of cancer stem cells;
3. the identification of biomarkers for cancer patients’ responsiveness to immunotherapy and that can predict the risk of development of colorectal for IBD patients.
• Ability to develop and maintain own knowledge and skills at the forefront of field
• Effective problem solving and analytical skills and ability to be detail oriented
• Demonstrated ability to write and edit scientific information for a general audience
• Ability to assist in the management of a project, overcome obstacles, and meet deliverable deadlines
• Fluency in written and spoken English
Sidra Medicine is a state-of-the-art Academic Hospital committed to providing women and children in Qatar with world-class tertiary healthcare services.
Sidra Medicine is also part of a dynamic research and education environment in Qatar and through strong partnerships with leading institutions around the world.
Interested applicants should submit their candidature through the Sidra Medicine Website:
A well-funded, dynamic and question-driven young lab at The University of Texas MD Anderson Cancer Center seeks to appoint one or more highly motivated postdoctoral fellows with a strong interest in cancer biology, tumor immunology and cancer immunotherapy and a desire to work with projects related to lung cancers. The successful appointee(s) will be working under the supervision of Tina Cascone, M.D., Ph.D., Assistant Professor, physician-scientist in the Department of Thoracic/Head and Neck Medical Oncology. The project and research opportunities for the postdoctoral candidate will focus on investigating T cell-mediated mechanisms of tumor response and resistance to immune-based therapies in non-small cell lung cancer (NSCLC), using innovative preclinical murine models and clinical samples from cutting-edge trials evaluating immune-based therapies for patients with NSCLC. The opportunity to conduct translational research by studying relevant preclinical models and human samples will improve our ability to develop more effective therapeutic strategies for patients with lung cancer and other cancers and advance the field of cancer immunotherapy.
Qualified candidates should have a doctoral degree, with strong background in one or more of the following areas: tumor immunology and cancer immunotherapy, molecular biology, cell biology, cancer biology, and biochemistry, with an emphasis on mechanisms of action of immune checkpoint inhibitors and T cell-based therapies (required). Prior experience in understanding, generating, and handling murine models of cancer, as well as ability to analyze data derived from in vivo studies using syngeneic mouse models of cancer is desired. Expertise in any of the following fields would be considered advantageous, but is not essential: oncogenic signaling pathways, biomarkers of response and resistance to cancer therapies (targeted therapies, antiangiogenic therapies and immune-based therapies), cancer metabolism, and immuno-genomics. The postdoctoral fellow is expected to be a self-starter, highly motivated, dedicated, have critical thinking abilities, excellent technical skills, strong work ethic, and excellent organizational and communication skills.
MD Anderson is ranked one of the top two hospitals in cancer care nationwide for 25 years by U.S. News & World Report. The cancer center ranks high in the number of National Cancer Institute grants and invests millions in research every year; it offers active graduate and post-doctoral training programs, and the unmatched scientific environment of the Texas Medical Center, the world's largest biomedical center.
For those interested, please send a CV, three letters of recommendation, and a 2-3 page research statement describing past achievement s, skills and research interests to Michelle Morris -firstname.lastname@example.org.
MD Anderson Cancer Center is an equal opportunity employer and does not discriminate on the basis of race, color, national origin, gender, sexual orientation, age, religion, disability or veteran status except where such distinction is required by law. All positions at The University of Texas MD Anderson Cancer Center are security sensitive and subject to examination of criminal history record information. Smoke-free and drug-free environment.
Application Deadline: the position will be open until filled
We are seeking a creative and highly motivated postdoctoral fellow (PhD, MD/PhD or equivalent) experienced in tumor immunology, immunotherapy, T and B cell biology or other relevant areas to participate in translational research projects aimed at elucidating the impact of T cell regulatory mechanisms and anti-tumor humoral immunity in the response to cancer immunotherapy. Research projects involve, but are not limited to: 1) the analysis of conventional and non-conventional immunosuppressive CD4+ T cells as mechanisms of resistance to immunotherapy; 2) the role of antibody responses in the anti-tumor activity of immune checkpoint blockade therapy; and 3) the study of the immune microenvironment in the pathogenesis of B cell lymphomas and its role in their response to immunotherapy. The candidate will work within a multidisciplinary team of translational scientists, computational biologists, and clinicians at the Weill Cornell Medical College, in the Division of Hematology and Medical Oncology and the Meyer Cancer Center.
The Zappasodi Lab
Dr. Roberta Zappasodi is an Assistant Professor of Hematology in Medicine in the Division of Hematology and Medical Oncology of the Department of Medicine at the Weill Cornell Medical College. She is an award-winning investigator, whose research focuses on the role of the adaptive immune system and specific immune subsets in solid tumors and hematologic neoplasms, their prognostic role and therapeutic potential. As a Parker Bridge Fellow, Dr. Zappasodi is also supported by the Parker Institute for Cancer Immunotherapy.
The Zappasodi Lab is located in the state-of-the-art Belfer Research Building (BRB), opened in 2014 in the heart of the Upper East Side in New York City. Its proximity to the adjacent Weill Greenberg Center and the medical college’s hospital ensures that breakthroughs made in the laboratory can be quickly and seamlessly transferred to patient care. The BRB is embedded in the Tri-Institutional Campus, encompassing the Weill Cornell Medical College, Memorial Sloan Kettering Cancer Center, and the Rockefeller University.
Interested applicants should send the following materials in an application packet, preferably as a single PDF file, by email to Prof. Roberta Zappasodi (email@example.com):
One post-doctoral position, sponsored by the Italian Association for Cancer Research (AIRC), is immediately available in the Cellular Immunology Unit, Division of Immunology, Transplantation and Infectious Diseases,
at the San Raffaele Scientific Institute, Milan, Italy.
The position is offered to investigate the molecular basis of the interactions between the microbiota and the
immune system driving multiple myeloma aggressiveness. The interested candidate can check our recent
publications in this area to get more insights on the project:
• Bellone M, et al. Microbiol Mol Biol Rev 2020 (doi: 10.1128/MMBR.00064-19)
• Calcinotto A, Brevi A, et al. Nat Commun 2018 (doi: 10.1038/s41467-018-07305-8)
• Calcinotto A, et al., OncoImmunology 2015 (PMID: 26155424)
The successful applicant will participate in a work team that combines high-dimensional multicolor flow
cytometry, metagenomics, and genetically engineered mouse models to unveil immunological changes
across the gut-bone marrow networks in both humans and preclinical models of multiple myeloma.
Ambitious, and self-motivated ideal candidates for the position with relevant education or experience in
immunology are invited to apply, though preference will be given to candidates with experience in flow
cytometry. Demonstration of excellent teamwork and collaborative skills will be highly desirable. Please send
your curriculum vitae, a brief description of research interests and career goals, and contact information for
two references to Dr. Matteo Bellone, via email at: Bellone.firstname.lastname@example.org
The San Raffaele Scientific Institute is a private organization that includes a research hospital recognized by
the Italian Ministry of Health, a research institute and the associated Vita-Salute San Raffaele University.
Integrated clinical, research and training activities are conducted with > 1,300 beds, around 1,600 basic,
clinical and translational scientists, and almost 3000 students. A common campus hosts all teaching, basic,
translational and clinical research activities in a large infrastructural compound. Hence, the San Raffaele
offers the opportunity to work in a unique environment where basic, translational and clinical research Units,
hospital Departments and teaching activities effectively interact on a daily basis. Mission of the San Raffaele
Scientific Institute is to advance the knowledge on human diseases, and to identify novel therapies through
basic and translational research. More information can be found at:
We are looking for an outstanding and highly motivated Scientist to work on the AIRC-funded research project (from February 2021):
“Targeting IL-10 producing regulatory T-cells in cancer”
The ideal successful candidate should have experience with mouse cancer models, lymphocyte culture (both human and murine),
flow cytometry and molecular biology techniques. The ideal candidate also should be available to work part of the time
in Italy (Milan) and in Bellinzona (Switzerland).
Häringer et al., J Exp Med 2009
Geginat et al., Cyt Growth Fact Rev 2016
Alfen et al., J Allergy Clin Immunol 2018
J Geginat (Editorial), Semin Immunol 2019
Gruarin et al., Eur J Immunol 2019
Please send your CV to Jens Geginat email@example.com - https://ingm.org/en/geginat_lab_eng
ISTITUTO NAZIONALE GENETICA MOLECOLARE “Romeo ed Enrica Invernizzi”
Via Francesco Sforza, 35 – 20122 Milano, Italia
Tel. +39 02 0066 0211– Fax +39 02 0066 0216 – E-mail: firstname.lastname@example.org
Codice Fiscale 04175700964
A research position is immediately available in the laboratory of Dr. Maria Pia Protti at the
Tumor Immunology Unit, Division of Immunology, San Raffaele Scientific Institute of Milan.
The major interest in the laboratory is the study of the tumor microenvironment, and in
particular of the immune cell infiltrates with anti- versus pro-tumor functions with special
emphasis on the role of T helper (Th) cells.
In the last years we focused on pancreatic ductal adenocarcinoma and we identified a tumorpromoting
function for tumor infiltrating Th2 cells that depends on a complex cross-talk
between tumor cells, cancer associated fibroblasts and immune cells, within the tumor
microenvironment and tumor draining lymph nodes, among which monocytes, tumor
associated macrophages, dendritic cells, T cells and basophils (De Monte L et al., J Exp Med
2011; 208:469; De Monte L et al., Cancer Res 76:1792). Cytokines and soluble factors key to
the development of Th2 inflammation were also identified, and specifically tumor-derived IL-
1 and cancer associated fibroblast-derived thymic stromal lymphopoietin (TSLP) (Brunetto E,
De Monte L et al., J Immunother Cancer 2019;7:45). Targeting of these molecules might
impact on the immunosuppressive tumor microenvironment by repolarizing the immune
contexture towards anti-tumor Th1 inflammation.
The candidate will be involved in the study of mechanisms of immunosuppression in the
pancreatic cancer microenvironment, and of development of therapeutic strategies targeting
molecules/cytokines of interest. These studies are conducted in the framework of an
international EURONANOMED program testing in vitro and in vivo targeting strategies based
on the delivery of therapeutics by nanoparticles. Specifically, the efficacy of blocking IL-1
availability in the tumor microenvironment using the IL-1R antagonist molecule incorporated
in nanoparticles will be first tested.
We are looking for a highly motivated candidate (either a junior or post-doctoral fellow) with
strong interest in immunology, and experience in cellular immunology and basic molecular
biology. Experience in fluorescence and confocal microscopy would be considered a plus.
Interested candidates should send their CVs, a brief statement of research and career interest,
and at least one contact information for references to: email@example.com
with proved experience in the field of human T cell immunobiology and T cellengineering.
The position is initially limited to three years with the possibility to be continued and is remunerated on the TV-L salary scale (TV-L EG 14)
The RCI - Regensburg Center for Interventional Immunology (foundation under public law) is a novel biomedical research center focusing on translational immunology in the
fields of cancer immunotherapy, transplant rejection and autoimmunity. The objective of the RCI is to develop effective immune therapeutic strategies in these areas.
The senior scientist will be responsible for the development of clinical-grade protocols
for the manufacturing of gene-engineered T cells that will be employed in Phase 1/2
clinical studies at the University Hospital Regensburg. Projects derive from recent basic
research and translational pre-clinical studies conducted at the RCI and primarily within
the Department of Functional Immune Cell Modulation. Gene manipulations encompass
the modulation of transcription factors, microRNAs and metabolic checkpoints coupled
with CAR and TCR platforms to functionally improve the antitumor efficacy of generedirected
Responsibilities include, but are not limited to:
• Perform all tasks associated with the manufacturing of clinical-grade cell
products including the development of standard operating procedures (SOPs),
batch records and other GMP documentation.
• Design and conduct clinical assays required to support assessment of T cell
• Successfully troubleshoot processing and equipment issues.
The ideal candidate possesses:
• PhD in Molecular Biology, Cell Biology, Immunology or a relevant discipline and
5 or more years of cGMP experience in a T cell manufacturing and biotechnology
• Extensive experience in isolating, culturing human T cells.
• Extensive experience with virus-based and nonviral gene delivery platforms.
• Experience with automated processing equipment.
• Strong knowledge of cGMP regulations and experience in writing SOPs and documentation associated with clinical-grade cell manufacturing.
• Excellent communications skills, both oral and written in English. •Strong analytical, organizational and time management skills.
The RCI follows the goal of professional equality for all genders and therefore strongly encourages qualified women to apply. In addition, the RCI supports work-family balance.
The RCI is an equal opportunity employer and candidates with disabilities will be given preference, provided they are equally qualified.
If we have awakened your interest and you are open to new professional challenges, we would be delighted to receive an informative application from you.
Please send your full application including a statement of interest, curriculum vitae, certificates, expected availability date, a list of publications and 2-3
references by e-mail to Prof. Dr. Philipp Beckhove (firstname.lastname@example.org). Application deadline is June 30, 2020.
RCI – Regensburger Centrum für Interventionelle Immunologie
c/o Universitätsklinikum Regensburg
For more information contact : Prof. Luca Gattinoni (e-mail: email@example.com phone: +49 941 944 38132)